Page last updated: 2024-09-03

imatinib mesylate and Anemia, Refractory

imatinib mesylate has been researched along with Anemia, Refractory in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A	1
Shannon, KM; Van Etten, RA	1
Azzarà, A; Cannizzo, E; Carulli, G; Galimberti, S; Petrini, M; Zucca, A	1

Reviews

1 review(s) available for imatinib mesylate and Anemia, Refractory

Article	Year
Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer cell, 2004, Volume: 6, Issue:6 Topics: Anemia, Refractory; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Models, Biological; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Pyrimidines; Signal Transduction	2004

Other Studies

2 other study(ies) available for imatinib mesylate and Anemia, Refractory

Article	Year
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood, 2003, Apr-15, Volume: 101, Issue:8 Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy	2003
JAK-2V617F mutation in RARS-t: a target for Imatinib therapy? Leukemia research, 2008, Volume: 32, Issue:10 Topics: Aged; Amino Acid Substitution; Anemia, Refractory; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Piperazines; Platelet Count; Point Mutation; Protein Kinase Inhibitors; Pyrimidines	2008

Article

Year

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

Blood, 2003, Apr-15, Volume: 101, Issue:8

Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy

2003

JAK-2V617F mutation in RARS-t: a target for Imatinib therapy?

Leukemia research, 2008, Volume: 32, Issue:10

Topics: Aged; Amino Acid Substitution; Anemia, Refractory; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Piperazines; Platelet Count; Point Mutation; Protein Kinase Inhibitors; Pyrimidines

2008